Abstract: The present invention relates to artificially designed polypeptides having RNA-targeting and editing activity, wherein said polypeptides are fusion proteins comprising a modified ADAR2 deaminase domain and a Cas family targeting moiety selected from deactivated Cas13b and CasRx. Further encompassed are methods for use and uses of these polypeptides, compositions comprising them and nucleic acids encoding them as well as methods for the manufacture of said polypeptides.

Abstract: The present invention relates to a polypeptide comprising at least one at least one deletion selected from the group consisting of ?HNH (?775-909), ARuvCIII-b (?1002-1074), AREC1-a (?510-655), AREC1-b (?525-587), AREC1-c (?662-710), AREC2 (?180-308), AREC2-a (?212-244), AREC2-b (?244-276), AREC2-c (?276-308), AREC2-d (?199-283), AREC2-e (?198-257), AREC2-f (?235-286), AREC2-g (?217-266), AREC3 (?498-712) and combinations thereof, wherein the position numbering is in accordance with SEQ ID NO: 1 encoding for S. pyogenes Cas9, and wherein the polypeptide has CRISPR-Cas DNA-binding activity. The polypeptide may further comprises a missense mutations selected from G12R, T13K, T13R, N14K, N497K, T657K, T657R, N767K, T770K, T770R, Q920K, Q920R, S1109R, D1135K, D1135R, S1338R and combinations thereof. Also claimed are nucleic acid molecules encoding for said polypeptides, compositions and method of site-directed engineering of a target DNA thereof.

Abstract: The present invention is in the field of molecular diagnostics and is directed to the detection of target nucleic acids in a sample using a modified CRISPR-Dx system, typically with prior amplification of the target. The modified CRISPR-Dx system comprising an engineered E174R/S542R/K548R variant of AsCas12a, wherein when get activated indiscriminately cleaves at least one detection reagent to generate signal. In one embodiment, the target nucleic acid is SARS-CoV-2 RNA.

Abstract: The present invention relates to a polypeptide comprising at least one at least one deletion selected from the group consisting of ?HNH (?775-909), ARuvCIII-b (?1002-1074), AREC1-a (?510-655), AREC1-b (?525-587), AREC1-c (?662-710), AREC2 (?180-308), AREC2-a (?212-244), AREC2-b (?244-276), AREC2-c (?276-308), AREC2-d (?199-283), AREC2-e (?198-257), AREC2-f (?235-286), AREC2-g (?217-266), AREC3 (?498-712) and combinations thereof, wherein the position numbering is in accordance with SEQ ID NO: 1 encoding for S. pyogenes Cas9, and wherein the polypeptide has CRISPR-Cas DNA-binding activity. The polypeptide may further comprises a missense mutations selected from G12R, T13K, T13R, N14K, N497K, T657K, T657R, N767K, T770K, T770R, Q920K, Q920R, S1109R, D1135K, D1135R, S1338R and combinations thereof. Also claimed are nucleic acid molecules encoding for said polypeptides, compositions and method of site-directed engineering of a target DNA thereof.